Literature DB >> 15279911

Differential expression of adenylyl cyclase subtypes in human cardiovascular system.

T Wang1, M J Brown.   

Abstract

In human myocardium, beta1-adrenoceptor stimulation achieves maximal inotropic response but less than 50% of maximal adenylyl cyclase activation, whereas the reverse is true of the beta2-adrenoceptor. Four types of adenylyl cyclase, type IV-VII, have been described in mammalian heart, but their expression and relative distribution in human heart and blood vessels is not known. We found that type IV, V, VI and VII adenylyl cyclases were all expressed in cardiomyocytes. Whereas types IV and VII RNA were more abundant in extra-cardiac than cardiac tissues, both absolute and relative expression of type VI was greatest in heart, and lower in tissues lacking a beta1-adrenoceptor. Type V expression was virtually confined to atrium. In situ mRNA hybridisation showed that the beta1-adrenoceptor co-localised with type VI adenylyl cyclase but not other subtypes in juxtoglomerular cells of human kidney. The tissue specific expression of these adenylyl cyclase subtypes may favour its coupling to corresponding receptors expressed in the given tissue type.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15279911     DOI: 10.1016/j.mce.2004.05.012

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  15 in total

Review 1.  Choreographing the adenylyl cyclase signalosome: sorting out the partners and the steps.

Authors:  Rennolds S Ostrom; Amy S Bogard; Robert Gros; Ross D Feldman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-20       Impact factor: 3.000

2.  Stimulation of renin secretion by catecholamines is dependent on adenylyl cyclases 5 and 6.

Authors:  Fadi Aldehni; Tong Tang; Kirsten Madsen; Michael Plattner; Andrea Schreiber; Ulla G Friis; H Kirk Hammond; Pyung Lim Han; Frank Schweda
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

Review 3.  Cardiac GPCRs: GPCR signaling in healthy and failing hearts.

Authors:  Natasha C Salazar; Juhsien Chen; Howard A Rockman
Journal:  Biochim Biophys Acta       Date:  2007-02-20

Review 4.  Inhibitors of membranous adenylyl cyclases.

Authors:  Roland Seifert; Gerald H Lushington; Tung-Chung Mou; Andreas Gille; Stephen R Sprang
Journal:  Trends Pharmacol Sci       Date:  2011-11-17       Impact factor: 14.819

5.  Impairment of adenylyl cyclase 2 function and expression in hypoxanthine phosphoribosyltransferase-deficient rat B103 neuroblastoma cells as model for Lesch-Nyhan disease: BODIPY-forskolin as pharmacological tool.

Authors:  Liz Kinast; Juliane von der Ohe; Heike Burhenne; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-03       Impact factor: 3.000

Review 6.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

7.  Compartmentation of cAMP signaling in cardiac myocytes: a computational study.

Authors:  Radu V Iancu; Stephen W Jones; Robert D Harvey
Journal:  Biophys J       Date:  2007-02-09       Impact factor: 4.033

Review 8.  Renin: friend or foe?

Authors:  Morris J Brown
Journal:  Heart       Date:  2007-05-08       Impact factor: 5.994

9.  Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.

Authors:  John A Meyers; Derrick W Su; Adam Lerner
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

10.  Adenylyl cyclase type 5 protein expression during cardiac development and stress.

Authors:  Che-Lin Hu; Rachna Chandra; Hui Ge; Jayashree Pain; Lin Yan; Gopal Babu; Christophe Depre; Kousaku Iwatsubo; Yoshihiro Ishikawa; Junichi Sadoshima; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-04       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.